Alexandria Real Estate Equities
ARE
$48.87
-7.84%
Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT) that develops, redevelops, and operates office and laboratory space for life science, agtech, and technology tenants. As a leading life science REIT, it has established a dominant presence in key innovation clusters including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The company is currently navigating a challenging environment marked by a significant decline in its stock price over the past year, driven by concerns over rising interest rates, weakening demand for office space, and a recent quarterly loss that has raised questions about its near-term earnings power. Investors are closely watching management's ability to stabilize occupancy, control costs, and leverage its high-quality life science portfolio to recover from the current downturn.…
ARE
Alexandria Real Estate Equities
$48.87
Investment Opinion: Should I buy ARE Today?
Rating: Hold. The consensus recommendation is Hold with an average target of $51.00, implying a slight downside of -0.9% from the current price. The thesis is that ARE's high-quality life science portfolio and positive FCF provide a floor, but the massive Q4 loss and revenue decline warrant caution until fundamentals stabilize.
Sign up to view all
ARE 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The company's core assets are high-quality, but the financial performance is currently poor. The stock is trading near fair value based on analyst targets, but the negative earnings and high leverage limit upside. If revenue growth turns positive and impairments cease, the stance would upgrade to bullish. Conversely, if the dividend is cut or further losses occur, it would downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alexandria Real Estate Equities's 12-month outlook, with a consensus price target around $51.00 and implied upside of +4.4% versus the current price.
Average Target
$51.00
0 analysts
Implied Upside
+4.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$42 - $60
Analyst target range
The target price range spans from a low of $42.00 to a high of $60.00, representing a wide spread of approximately 43% from low to high, reflecting significant uncertainty about the company's future. The low target of $42.00 implies a downside of -18.4% from the current price, likely pricing in continued weakness in the office sector and potential further impairments. The high target of $60.00 suggests an upside of +16.6%, assuming a successful stabilization of occupancy and a recovery in life science leasing demand. The recent downgrade by BMO Capital and the absence of any upgrades in the past few months indicate that analysts are becoming more cautious, though the presence of Outperform ratings from Baird and Evercore ISI shows that some see value at current levels.
Bulls vs Bears: ARE Investment Factors
ARE presents a classic value trap versus turnaround debate. The bear case is strong: massive losses, revenue decline, high leverage, and a 32.7% stock drop highlight severe operational and financial stress. However, the bull case rests on the company's irreplaceable life science portfolio, healthy gross margins, positive FCF, and a valuation near historical lows. Currently, bearish evidence dominates due to the magnitude of the Q4 loss and lack of clarity on recovery. The key tension is whether the impairments are a one-time reset or a sign of structural decline in lab space demand. If occupancy stabilizes and losses reverse, the stock could re-rate significantly; if not, further downside toward the 52-week low is possible.
Bullish
- Dominant life science REIT franchise: ARE is the leading owner of life science real estate in top innovation clusters like Greater Boston, SF Bay Area, and San Diego. This specialized portfolio provides a competitive moat and long-term demand drivers from biotech and pharma R&D spending, despite near-term headwinds.
- Healthy gross margin at 69.2%: Gross margin remained robust at 69.18% in Q4 2025, reflecting the high-quality nature of its properties and pricing power. This provides a solid foundation for cash flow generation once occupancy stabilizes.
- Positive free cash flow of $1.41B: TTM free cash flow is $1.41 billion, indicating the company generates sufficient cash to cover dividends and debt obligations despite accounting losses. This supports financial stability and a potential recovery.
- Potential value at 52-week lows: The stock trades near $51.45, close to its 52-week low of $39.41, with a PS ratio of 2.81x below historical averages. This suggests much negative news is priced in, offering upside if fundamentals stabilize.
Bearish
- Massive Q4 net loss of $1.08B: Q4 2025 net loss of $1.08 billion, driven by $2.1 billion in other expenses, swung the TTM net margin to -48.15%. This severe profitability hit raises concerns about asset impairments and ongoing earnings power.
- Revenue declining YoY: Q4 revenue of $754.4 million was down 1.16% YoY, and the trend shows stagnation with Q3 at $735.8M and Q2 at $737.3M. This indicates weakening leasing demand and occupancy pressure.
- High leverage with D/E of 0.82: Debt-to-equity ratio of 0.82x and a current ratio of 0.43x highlight elevated leverage and liquidity constraints. Rising interest rates increase refinancing costs and pressure on cash flows.
- Negative earnings and PE: Trailing PE is -5.80x and forward PE is -58.47x, reflecting persistent losses. Analysts expect EPS of only $0.38 for the year, implying continued weakness and no near-term profitability.
ARE Technical Analysis
ARE's stock has been in a pronounced downtrend over the past year, with a 1-year price change of -32.68%, significantly underperforming the S&P 500's +18.19% gain. The current price of $51.45 sits at approximately 58.3% of its 52-week range (between $39.41 low and $88.24 high), indicating the stock is closer to its lows than its highs. This positioning suggests the market is pricing in substantial negative sentiment, but also that the stock may be approaching oversold conditions, potentially offering a value opportunity if fundamentals stabilize.
Beta
1.17
1.17x market volatility
Max Drawdown
-53.8%
Largest decline past year
52-Week Range
$39-$88
Price range past year
Annual Return
-36.6%
Cumulative gain past year
| Period | ARE Return | S&P 500 |
|---|---|---|
| 1m | -7.1% | +3.6% |
| 3m | +6.6% | +5.1% |
| 6m | -11.4% | +13.8% |
| 1y | -36.6% | +22.2% |
| ytd | -0.2% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARE Fundamental Analysis
Revenue for the most recent quarter (Q4 2025) was $754.4 million, a slight decline of 1.16% year-over-year, reflecting a deceleration from prior quarters. The company has experienced a multi-quarter trend of stagnant to slightly declining revenue, with Q3 2025 revenue at $735.8 million and Q2 2025 at $737.3 million, indicating a plateau. The gross margin remains healthy at 69.18%, but the company reported a net loss of $1.08 billion in Q4 2025, a dramatic swing from profitability in earlier quarters, driven by significant impairment charges and other expenses. This loss has pushed the trailing twelve-month net margin to -48.15%, highlighting severe profitability challenges.
Quarterly Revenue
$754414000.0B
2025-12
Revenue YoY Growth
-1.2%
YoY Comparison
Gross Margin
69.2%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARE Overvalued?
Given the negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 2.81x, which is below the historical average but still reflects a premium to the broader REIT sector. The forward PE is -58.47x, indicating that analysts expect earnings to remain negative in the near term, while the trailing PE is -5.80x, both meaningless due to losses. The EV-to-Sales ratio of 8.61x suggests that the market is valuing the company at a significant premium to its revenue, likely due to the high quality of its life science properties and long-term growth potential.
PE
-5.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~176x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
57.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are acute: the $1.08B Q4 net loss, driven by $2.1B in other expenses, has eroded equity and pushed the net margin to -48.15%. With a debt-to-equity ratio of 0.82x and a current ratio of 0.43x, the company faces liquidity pressure, especially if interest rates remain elevated. The negative EPS of -$6.35 for Q4 and forward PE of -58.47x indicate that earnings are not expected to recover soon, increasing reliance on asset sales or refinancing. Free cash flow of $1.41B provides some buffer, but it could be strained by dividend obligations (yield 10.9%) and debt maturities.